Laurence Klotz, MD, presented “MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Patients with Localized Prostate Cancer” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Klotz, Laurence. “MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Patients with Localized Prostate Cancer” January 23rd, 2020. Accessed Jul 2024. https://grandroundsinurology.com/mri-guided-transurethral-ultrasound-ablation-tulsa-for-prostate-cancer/
MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Patients with Localized Prostate Cancer – Summary:
Laurence Klotz, MD, Professor of Surgery at the University of Toronto and Sunnybrook Chair of Prostate Cancer Research, discusses a newly FDA-approved treatment of localized prostate cancer: MRI-guided transurethral ultrasound ablation (TULSA). He explains how using MRI improves ablation technique, offers a technical overview of the procedure, and then reviews clinical trials of TULSA. As Dr. Klotz describes, MRI thermometry allows physicians to see what temperature the tissue is reaching during ablation, and the use of urethral and rectal cooling helps protect the urethra, making TULSA an effective treatment. He then explores a clinical study of MRI-guided TULSA conducted in five countries that showed a significant reduction of the prostate with minimal adverse effects.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Klotz gave this presentation during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Laurence Klotz, MD, FRCSC, is a professor of surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research. Dr. Klotz was the founding editor-in-chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal (CUAJ), and he is now editor emeritus of the CUAJ. Dr. Klotz obtained his medical degree and completed his residency at the University of Toronto. He was also a uro-oncology fellow at Memorial Sloan Kettering Cancer Center in New York.
Dr. Klotz has 550 peer review publications and eight books. He coined the phrase “active surveillance” and successfully championed this approach for men with favorable-risk prostate cancer against substantial resistance. He was the associate editor of the Journal of Urology, responsible for prostate cancer, for eight years. Dr. Klotz received the Queen’s Jubilee Medal for outstanding public service, the University of Toronto's Lister Prize, the Society of Urologic Oncology’s SUO Medal, the American Urological Association’s Richard Williams Award, the University of Toronto's Lifetime Achievement Award, the Canadian Urological Association Lifetime Achievement Award, and the Harold Warwick Award from the Canadian Cancer Society for “outstanding contributions to cancer control.” In 2015 he was inducted as a Member of the Order of Canada, Canada’s highest civilian award.